INOVIO Pharmaceuticals

INOVIO’s INO-3107 Shows Sustained Long-Term Benefits for Patients With Recurrent Respiratory Papillomatosis

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported new peer-reviewed findings demonstrating that its investigational DNA immunotherapy, INO-3107, continues to deliver long-term clinical benefits for patients with recurrent respiratory papillomatosis …

INOVIO’s INO-3107 Shows Sustained Long-Term Benefits for Patients With Recurrent Respiratory Papillomatosis Read More